Pharmanest Phase II SHACT study meets efficacy and safety end points

Karolinska Development has reported that the Pharmanest Phase II study of SHACT, a proprietary four percent lidocaine formulation, met all efficacy and safety end points.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news